Monday, June 15, 9:00 – 10:30 am
Auditorium Lulli

Chairs: Markus Moehler (Germany) – Dave H. Wang (USA) 

1. Early-onset gastroesophageal cancer – a distinct entity? – Irit Ben-Aharon (Israel)
2. After neoadj therapy with (n)cCR, local endoscopic resections? – Pech Oliver (Germany)
3. Pro: First joice Chemo (instead of CROSS) in adenocarcinoma of esophagus. – Eduardo Terán (Spain)
4. Contra: First joice CROSS (instead Chemo) in adenocarcinoma of esophagus. – Mike Gibson (USA)
5. De-escalation strategies in oesogastric adenocarcinomas: is the time right? – Christelle De la Fouchardière (France)
6. Young or old: Do we differentiate in intensity of multimodal care? Dave H. Wang (USA) 
7. MSI: how do we treat, w+w or operate? – Thierry André (France)
8. ASCO 2026: New important SOC-changing phase III trials? – Lucjan Wyrwicz (Poland)
9. Multidisciplinary tumor board in gastric and gastroesophageal cancer: Harmonizing local, systemic, and geriatric considerations. – Hanoch Kashtan (Israel)
10. Decision making and translational research: Challenges and evidence in tumor conferences. – TBD
11. Sport program and Resilience: what helps in perioperative setting? – Katja Petrowski (Denmark)